(GSK) |
| 0 (0%) 07-28 00:00 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 54.29 |
| Resistance 1: | 52.61 |
| Pivot price: | 51.75 |
| Support 1: | 49.89 |
| Support 2: | 41.51 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 3.800 |
| Book Value | 0.000 |
| PEG Ratio | 19.17 |
| Gross Profit | 11.945 |
| Profit Margin (%) | 17.78 |
| Operating Margin (%) | 36.28 |
| Return on Assets (ttm) | 10.0 |
| Return on Equity (ttm) | 40.9 |
Company news
Mon, 27 Jul 2026
GSK Earnings Preview: EPS to take a plunge; CEO's comments, guidance in focus - Seeking Alpha
Mon, 27 Jul 2026
Earnings To Watch: GSK PLC (LSE:GSK) Reports Q2 2026 Result - GuruFocus
Fri, 17 Jul 2026
GSK shelves cough drug acquired in $2B deal - BioPharma Dive
Fri, 17 Jul 2026
GSK axes key cough drug candidate after phase 3 data disappoint - Fierce Biotech
Thu, 11 Jun 2026
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - Reuters
Tue, 09 Jun 2026
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push - WSJ
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
